louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05697484: The Impact of Arabic Gamified Mobile Application on Diabetes Control in Egyptian Pediatric Patients With Type 1 Diabetes.
Official title: The Impact of Arabic Gamified Mobile Application on Diabetes Control in Egyptian Pediatric Patients With Type 1 Diabetes.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Diabetic Pediatric Patients With Type 1 Diabetes
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-01-26
Enrollment: 76
Sex: ALL
Minimum age (years): 7
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a prospective randomized parallel two group pharmacist-led interventional study. The study will involve introduction of the mobile game to pediatric diabetic patients to improve their blood glucose level. The outcomes to be measured are diabetes control and behavioral change in pediatric patients with type1 diabetes mellitus


Eligibility criteria: Inclusion Criteria:

1. Pediatric patients age from 7 to 14 years old to be able to deal with and understand the game.
2. Children previously diagnosed with type1 DM.
3. Arabic speaker.
4. Smart phone (android) access at home, either the mobile of the child or his/her parents.

Exclusion Criteria:

1. Severe cognitive or psychiatric conditions that prevent a patient from understanding the game. any disorder that significantly impairs the cognitive function of an individual to the point where normal functioning in society is impossible without treatment ,examples: dementia- developmental disorders-motor skills disorders- amnesia- substance induced cognitive impairment)25
2. Diabetic pediatric patients at goal with HbA1c \< 7.

Primary outcomes:
measure: diabetes control
timeFrame: 3 months
Secondary outcomes:
measure: Behavioral change
timeFrame: 3 months
measure: Measurement of blood glucose control
timeFrame: 3 months
measure: Usability and satisfaction
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05528484: Self-reported Outcomes of Patients in ERAS Nursing
Official title: Effect of ERAS Nursing on Self-reported Outcomes of Patients Undergoing Minimally Invasive Lung Cancer Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Enhanced Recovery After Surgery
Lead sponsor: The Second Hospital of Shandong University
Sponsor class: OTHER
First posted: 2022-09-06
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: We aimed to evaluate the effect of ERAS nursing program on self-reported outcomes of patients undergoing minimally invasive lung cancer surgery, and compared the differences in length of hospital stay, complications, and readmission rate between ERAS and non-ERAS nursing programs


Eligibility criteria: Inclusion Criteria:

* ≥18years,Minimally invasive elective surgery,cooperate

Exclusion Criteria:

* Pneumonectomy was performed and converted to open surgery

Surgery intensive care, unable to cooperate (language

Speech disorders, psychopathology)

Primary outcomes:
measure: Self-reported Outcomes of Patients(PRO)
timeFrame: at baseline, daily after surgery, and weekly up to 4 after discharge weekly.
Secondary outcomes:
measure: length of stay (LOS), postoperative cardiopulmonary complications (CPC) and readmission rate (READM)
timeFrame: From admission to one month after the patient's discharge
Other outcomes:
Locations:
city: Jinan
country: China
facility: The second hospital of shandong university
state: Shandong
Study officials:
References:
Clinical trial NCT00578084: Lung Cancer Location: a Repository
Official title: Lung Cancer Location: A Prospective Repository
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Lung Cancer
Lead sponsor: Indiana University
Sponsor class: OTHER
First posted: 2007-12-20
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with known or suspected lung cancer will be identified by referral to the thoracic surgeon or ultrasonographer at the Veterans Affairs Hospital or Indiana University Medical Center.

Brief summary: The purpose of this repository is to prospectively examine subjects with known or suspected lung cancer to determine the extent of mediastinal lymph node involvement with respect to primary lung cancer location. The data collected in this repository may be used to influence our current standard of care and streamline indications for EUS.


Eligibility criteria: Inclusion Criteria:

* Subjects undergoing EUS evaluation of a mediastinal mass, or suspected/known lung cancer
* Subjects with a prior history of lung cancer
* Subjects referred to thoracic surgery for evaluation of a suspected/known lung cancer

Exclusion Criteria:

* Altered mental status that would prohibit the giving and understanding of informed consent
* Dementia
* Psychiatric illness that would preclude adequate compliance with communication for this protocol
* Prisoners

Primary outcomes:
measure: examine subjects with known or suspected lung cancer to determine the extent of mediastinal lymph node involvement with respect to primary lung cancer location
timeFrame: ongoing-database
Secondary outcomes:
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Clarian/IUPUI: University Hospital
state: Indiana
Study officials:
affiliation: Indiana University
name: Julia LeBlanc, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02186184: Effect of Orthokeratology Versus Spectacles on Myopia Progression in Chinese Children: A Crossover Trial
Official title: Effect of Orthokeratology on Myopia Progression in Chinese Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Myopia
Keywords: Myopia progression
Orthokeratology
Lead sponsor: Beijing Tongren Hospital
Sponsor class: OTHER
First posted: 2014-07-10
Enrollment: 100
Sex: ALL
Minimum age (years): 7
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Orthokeratology is becoming popular for the treatment of myopia children. Many studies have shown that orthokeratology is effective in temporarily reducing refractive error, and is also helpful for controlling myopia progression. However, the mechanism for its slowing myopia progression and rebound effect after the treatment have not been clearly studied. In addition, the effect of orthokeratology among Chinese children has not been evaluated with randomized controlled trial.This study is to assess the effect of orthokeratology versus spectacles on myopia progression in school-aged Chinese children during two years.


Eligibility criteria: Inclusion Criteria:

* Ages Eligible for Study: 7 Years to 14 Years
* Genders Eligible for Study: Both
* Visual acuity 20/20 or better in each eye
* Spherical error ranging from -0.5 D to -5.0 D and astigmatism less than 1.5 D in each eye, anisometropia less than 1.0 D between the two eyes
* No strabismus, amblyopia and any other ocular or systematic diseases that may affect refractive development

Exclusion Criteria:

* Currently or history using other interventions to control myopia progression (acupuncture, drugs, contact lens, ear needles and so on)
* Unable to cooperate with the ocular examination,questionnaire survey,or orthokeratology wearing

Primary outcomes:
measure: Refraction
timeFrame: Change from baseline at 1 year
measure: Axial length
timeFrame: Change from baseline at 1 year
measure: Refraction
timeFrame: Change from baseline at 2 years
measure: Axial length
timeFrame: Change from baseline at 2 years
Secondary outcomes:
measure: Tear film break up time(BUT)
timeFrame: Change from baseline at 1 year
measure: Self evaluation of comfortableness
timeFrame: Change from baseline at 1 year
measure: Corneal endothelial cell density
timeFrame: Change from baseline at 1 year
measure: Tear film break up time(BUT)
timeFrame: Change from baseline at 2 years
measure: Self evaluation of comfortness
timeFrame: Change from baseline at 2 years
measure: Corneal endothelial cell density
timeFrame: Change from baseline at 2 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Tongren Hospital
state: Beijing
Study officials:
affiliation: Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University
name: Ningli Wang, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02005484: A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
Official title: An Open-label Pilot Study of Herceptin Monotherapy on Objective Treatment Response in Patients With Metastatic or Locally Advanced Gastric Cancer Who Had Disease Progression During Platinum-based or 5-fluoropyrimidine-based Chemotherapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Gastric Cancer
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2013-12-09
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will evaluate the efficacy and safety of Herceptin in patients with metastatic or advanced gastric cancer with disease progression during platinum-based or 5-fluoropyrimidine-based chemotherapy. The anticipated time on study treatment is until disease progression.


Eligibility criteria: Inclusion Criteria:

* adult patients 18-75 years of age;
* metastatic or advanced gastric cancer;
* disease progression under or after 1 prior platinum-based or 5-fluoropyrimidine-based chemotherapy for metastatic disease;
* \>=4 weeks from last platinum-based or fluoropyrimidine-based chemotherapy;
* \>=1 measurable lesion;
* HER2 overexpression (IHC \[2+\] or \[3+\]).

Exclusion Criteria:

* concurrent chemotherapy or immunotherapy;
* brain or meningeal metastases;
* clinically significant cardiac disease, advanced pulmonary disease or severe dyspnoea;
* co-existing malignancies or malignancies diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ;
* women who are pregnant or breastfeeding.

Primary outcomes:
measure: Percentage of Participants With a Response by Response Evaluation Criteria In Solid Tumors (RECIST) Category
timeFrame: Weekly throughout study
Secondary outcomes:
measure: Percentage of Participants With Clinical Benefit
timeFrame: Weekly throughout the study
measure: Percentage of Participants With a Best Overall Response of CR or PR
timeFrame: Weekly throughout the study
measure: Overall Survival - Number of Participants Who Died
timeFrame: Weekly throughout the study
measure: Overall Survival
timeFrame: Weekly throughout the study
measure: Time to Progression - Number of Participants With an Event
timeFrame: Weekly throughout the study
measure: Time to Progression
timeFrame: Weekly throughout the study
Other outcomes:
Locations:
city: Wien
country: Austria
city: Dresden
country: Germany
city: Erlangen
country: Germany
city: Essen
country: Germany
city: Grenzach-wyhlen
country: Germany
city: Halle
country: Germany
city: Kassel
country: Germany
city: Kiel
country: Germany
city: Mannheim
country: Germany
city: München
country: Germany
city: München
country: Germany
city: Oldenburg
country: Germany
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_CHAIR
References:
Clinical trial NCT03543384: Imaging of Facial Neuritis
Official title: Imaging of Facial Neuritis Using T2-weighted Gradient-echo Fast Imaging Employing Steady State Acquisition After Gadolinium Injection
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Facial Neuritis
Keywords: facial neuritis
T2 weighted gradient-echo
fast imaging employing steady state acquisition (FIESTA-C)
magnetic resonance imaging (MRI)
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2018-06-01
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with neuritis facial (neuritis group) who benefited, between 2009 and 2016, from an MRI of the internal auditory ducts, with gadolinous product injection and on the MRI 3 Tesla

Brief summary: Improved means of positive diagnosis of facial neuritis, the leading cause of peripheral facial palsy


Eligibility criteria: Inclusion Criteria:

* Age 18-80 years
* Subject giving their consent for their participation
* Patients with neuritis facial (neuritis group) who benefited, between 2009 and 2016, from an MRI of the internal auditory ducts, with gadolinous product injection and on the MRI 3 Tesla
* Patients with a perception deafness, without neuritis sign (control group) who also benefited from an MRI with gadolinous product injection on the MRI 3T with the same protocol.

Exclusion Criteria:

- Refusal to participate in the study

Primary outcomes:
measure: Presence or absence of pathologic enhancement of the facial nerve on the symptomatological side of the T2 sequence (FIESTA-C)
timeFrame: 1 hour after the realization of the MRI
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service Imagerie 1
Study officials:
affiliation: University Hospital, Strasbourg, France
name: Francis VEILLON, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03872284: Neuro-ophthalmology and Autoimmune Encephalitis (NODE)
Official title: Study of Neuro-ophthalmology Disorders in Autoimmune Encephalitis (NODE)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Autoimmune Encephalitis
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2019-03-13
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Men and women 18 to 70 years old diagnosed with autoimmune encephalitis

Brief summary: Autoimmune encephalitis represents a group of rare and heterogeneous neurological disorders. Pathophysiological mechanisms in these diseases are still unknown. Recently, oculomotor and neurovisual disorders have been described. Cerebral areas and neuronal networks associated with these abnormalities are well described. The investigator proposes to study and describe such neuro-ophthalmological disorders in a prospective cohort of patients with a autoimmune encephalitis, to better understand the pathophysiological basis of this neurological condition.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of autoimmune encephalitis
* With or without pathological antibody
* Aged from 18 to 70 years old
* Able to understand the aims and methods of this project
* Non opposed to the participation of this study

Exclusion Criteria:

* Other neurological, psychiatric or systemic conditions, which could induce neuro-ophthalmological signs Cognitive impairment, which is not linked to autoimmune encephalitis
* Ophthalmological condition, which could modify the interpretation of neuro-ophthalmological data Inability to remain seated
* Pregnancy or breast feeding
* Adults under guardianship

Primary outcomes:
measure: Percentage of patients presenting a neuro-ophthalmological abnormality.
timeFrame: Day 0
measure: Percentage of patients presenting neuro-ophthalmological abnormality.
timeFrame: At 6 months if an abnormality is found
Secondary outcomes:
Other outcomes:
Locations:
city: Bron
country: France
facility: Hospices Civils de Lyon
Study officials:
affiliation: Department of neuro-ophthalmology, Pierre Wertheimer university hospital
name: Caroline Tilikete, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00427284: Effect of Eplerenone on Endothelial Function in Patients With Stable Coronary Heart Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: Eplerenone auf die Endothelfunktion bei Patienten mit stabiler koronarer Herzkrankheit
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2007-01-29
Enrollment: 42
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with coronary heart disease

Brief summary: The aim of the present study is to investigate wether endothelial dysfunction associated with stable coronary artery disease is altered by selective aldosterone antagonism with Eplerenone as potential anti-inflammatory drug versus placebo.

Additionally we hypothesize that selective aldosterone antagonism reduces systemic inflammatory response such as C-reactive proteine, oxidative stress and pro-inflammatory cytokines.


Eligibility criteria: Inclusion criteria:

* Male patients (\> 30 years of age) with history of coronary artery disease (documented by coronary angiogram, nuclear imaging, positive stress test)
* Stable cardiovascular medication for at least 4 months Evaluation of the patients will take place at the Department of Internal Medicine, Cardiology, University Hospital Zurich.

Exclusion criteria:

* Evidence for myocardial infarction, unstable angina, stroke within 3 months prior to study entry
* coronary intervention/re-vascularisation procedure within 3 months prior to study entry
* long acting nitrates
* uncontrolled arterial hypertension, defined as RR\>160/90 mmHg
* congestive heart failure (\> NYHA I)
* Ejection fraction \<50%
* AV-Block\>I˚
* creatinine clearance \<50 mL/min
* insulin-dependent diabetes mellitus
* type 2 diabetes with microalbuminuria
* age \< 30 years
* anemia (Hb\<10 g/dl)
* malignancy chronic infection
* smoking
* serum potassium \>5.5 meq/L
* drug abuse
* potassium supplements or potassium-sparing diuretics (amiloride, spironolactone, or triamterene)
* concomitant use of strong inhibitors of CYP450 3A4 (e.g., ketoconazole, itraconazole)
* known history of Cushing disease or Morbus Addisons or diseases of the thyroid gland

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Division of Cardiology
state: ZH
Study officials:
affiliation: University Hospital Zurich, Division of Cardiology
name: Frank Ruschitzka, Prof MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06363084: A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Official title: Nimotuzumab Plus Adjuvant Chemotherapy vs Adjuvant Chemotherapy Alone for Resectable Pancreatic Cancer: a Propensity Score Matching Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Resectable Pancreatic Cancer
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2024-04-12
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer

Brief summary: This trial is a retrospective, observational study, patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer between 2016 and 2022 were selected and divided into two groups according to with (study arm) or without (control arm) nimotuzumab. The primary efficacy endpoint was overall survival (OS).

Detailed description: This trial is a retrospective, observational study based on real-world data obtained from the Health Information System (HIS) of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer between 2016 and 2022 were selected and divided into two groups according to with (study arm) or without (control arm) nimotuzumab. The primary efficacy endpoint was overall survival (OS).

Eligibility criteria: Inclusion Criteria:

* Age≥18 years old, gender is not limited;
* Confirmed by histopathological or cytological diagnosis of pancreatic cancer;
* Underwent surgical resection of the pancreas for non-metastatic pancreatic cancer (including resectable/borderline resectable pancreatic cancer, or locally advanced pancreatic cancer);
* Received Nimotuzumab plus adjuvant chemotherapy or adjuvant chemotherapy alone after surgery.

Exclusion Criteria:

* Patients with other primary malignancies other than pancreatic cancer;
* Evidence of recurrence or distant metastasis before surgery
* Received immunotherapy drugs (such as PD-1 inhibitors, etc.) used during adjuvant therapy, or proprietary Chinese medicines with anti-tumor indications, or hyperthermia, targeted therapy drugs other than nimotuzumab;
* Key information is missing (e.g., primary endpoint data were not available).

Primary outcomes:
measure: overall survival (OS）
timeFrame: approximately 84 months
Secondary outcomes:
measure: disease-free survival (DFS)
timeFrame: approximately 84 months
measure: locoregional recurrence-free survival (LRRFS)
timeFrame: approximately 84 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00207584: Randomized Controlled Trial of Doxycycline to Prevent Acquisition of Mycoplasma Pneumoniae in an Outbreak Setting
Official title: A Double-Blind, Randomized Placebo-Controlled Trial of Doxycycline for Chemoprophylaxis in the Setting of an Outbreak of Mycoplasma Pneumoniae
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mycoplasma Pneumoniae
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
First posted: 2005-09-21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: This study was designed to determine whether taking daily doxycycline during an outbreak of Mycoplasma pneumoniae could prevent a person from getting infected and interrupt ongoing disease transmission during an outbreak. Doxycycline is a treatment for Mycoplasma pneumoniae, but it is not certain that the drug could prevent disease if used prophylactically.


Eligibility criteria: Inclusion Criteria:

- Working at hospital facility where outbreak of Mycoplasma pneumoniae occured

Exclusion Criteria:

- Pregnant, on antiseizure medications, allergic to macrolide antibiotics

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Centers for Disease Control and Prevention
name: Julia A Schillinger, MD
role: PRINCIPAL_INVESTIGATOR
References: